The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The More, The Better: “Do the Right Thing” For Natural Killer Immunotherapy in Acute Myeloid Leukemia
|
|---|---|
| Published in |
Frontiers in immunology, October 2017
|
| DOI | 10.3389/fimmu.2017.01330 |
| Pubmed ID | |
| Authors |
Sarah Parisi, Mariangela Lecciso, Darina Ocadlikova, Valentina Salvestrini, Marilena Ciciarello, Dorian Forte, Giulia Corradi, Michele Cavo, Antonio Curti |
| Abstract |
Natural killer (NK) cells are circulating CD3(-) lymphocytes, which express CD56 or CD16 and an array of inhibitory receptors, called killer-immunoglobulin-like receptors (KIRs). Alloreactive KIR-ligand mismatched NK cells crucially mediate the innate immune response and have a well-recognized antitumor activity. Adoptive immunotherapy with alloreactive NK cells determined promising clinical results in terms of response in acute myeloid leukemia (AML) patients and several data demonstrated that response can be influenced by the composition of NK graft. Several data show that there is a correlation between NK alloreactivity and clinical outcome: in a cohort of AML patients who received NK infusion with active disease, more alloreactive NK cell clones were found in the donor repertoire of responders than in non-responders. These findings demonstrate that the frequency of alloreactive NK cell clones influence clinical response in AML patients undergoing NK cell immunotherapy. In this work, we will review the most recent preclinical and clinical data about the impact of alloreactive NK cells features other than frequency of alloreactive clones and cytokine network status on their anti-leukemic activity. A better knowledge of these aspects is critical to maximize the effects of this therapy in AML patients. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 1 | 10% |
| France | 1 | 10% |
| Mexico | 1 | 10% |
| Switzerland | 1 | 10% |
| Unknown | 6 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 70% |
| Scientists | 3 | 30% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 29% |
| Researcher | 8 | 21% |
| Professor | 4 | 11% |
| Student > Master | 3 | 8% |
| Lecturer | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 10 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 12 | 32% |
| Medicine and Dentistry | 5 | 13% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Agricultural and Biological Sciences | 3 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 10 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2017.
All research outputs
#7,344,629
of 25,932,719 outputs
Outputs from Frontiers in immunology
#8,280
of 32,608 outputs
Outputs of similar age
#108,938
of 340,113 outputs
Outputs of similar age from Frontiers in immunology
#183
of 566 outputs
Altmetric has tracked 25,932,719 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 32,608 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,113 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 566 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.